HLX71

Hengenix Biotech Inc · Phase 1 active Small molecule

At a glance

Generic name	HLX71
Also known as	Recombinant Human Angiotensin-Converting Enzyme 2-Fc Fusion Protein
Sponsor	Hengenix Biotech Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HLX71 CI brief — competitive landscape report
HLX71 updates RSS · CI watch RSS
Hengenix Biotech Inc portfolio CI